R-2487 in Patients With Rheumatoid Arthritis

ClinicalTrials.gov ID

NCT05961592

Lead Sponsor

Rise Therapeutics LLCINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

73Estimated

Last Update Posted

Jun 12, 2026Actual

Start Date

Oct 19, 2023Actual

Primary Completion Date

Nov 30, 2026Estimated

Completion Date

Dec 31, 2026Estimated

Official Title

A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis

Brief Summary

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis.

Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.

• Arthritis, Rheumatoid

• R-2487 DP

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Ages 18-75 years (Inclusive).
• Able to provide written informed consent.
• Men or women (not nursing or pregnant) who have active RA, defined as symptoms of RA prior to screening and have satisfied the ACR/EULAR 2010 criteria for the classification of RA prior to signing the informed consent.
• Subjects must have a CDAI > 10.0 at screening and have at least 3 tender and at least 3 swollen joints (excluding distal interphalangeal) at screening and at Day 1, based on the DAS28 joint count.
• Subjects may be able to be on hydroxychloroquine, methotrexate, and leflunomide. Sulfasalazine use is not permitted.
• Subjects may have received targeted synthetic DMARDs such as tofacitinib, baricitinib, and investigational therapies for RA if they have been washed out for 1 month prior to screening.
• Subjects receiving oral corticosteroids must be on a stable dose and at the equivalent of ≤10 mg prednisone daily for at least 4 weeks. Subjects may not receive an IM, IV or IA administration of a corticosteroid within 4 weeks prior to screening visit or initiation of therapy.
• All male and female subjects who are biologically capable of having children must agree to use a medically acceptable method of birth control for the duration of the study. All female subjects who are biologically capable of having children must have a negative pregnancy test result before administration of study drug. Any pregnancy that occurs in the female partner of a male subject in the trial must be reported if it occurs at any time during the study.
• Refrain from receiving any type of vaccinations during the study period (to include but not limited to influenza, COVID, shingles, tetanus, hepatitis, pneumonia, HPV, DPT, MMR, and polio).

Exclusion Criteria:

• Pregnancy (females, unless surgically sterile or at least two years post- menopausal must have a negative serum pregnancy test within 14 days prior to receiving the study drug and a negative urine pregnancy test on Study Day 0 before receiving the study drug).
• Nursing mothers.
• Subjects with autoimmune disease other than RA [e.g., psoriasis, systemic lupus erythematosus (SLE), vasculitis, seronegative spondylarthritis, Inflammatory Bowel Disease, Sjogren's syndrome] or currently active fibromyalgia.
• Subjects should not receive any of the following medications:
• Rituximab within 12 months prior to Day 1,
• Abatacept within 3 months prior to Day 1,
• Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or
• Mycophenolate mofetil within 2 months prior to Day 1, or
• Etanercept, Anakinra, Immunoglobulin, or blood products within 28 days prior to Day 1
• Prior immunotherapy, including systemic corticosteroids, such prednisone, biologics, Janus kinase (JAK) inhibitors (such as tofacitinib, baricitinib or upadacitinib), ozanimod, or investigational therapy must have completed at least 5 half-lives or 30 days, whichever is longer, prior to Day 0, unless otherwise specified. In the case of cell-depleting therapies, such as B or T cell depletion, cell counts must have recovered to acceptable or baseline levels (use of licensed agents for indications not listed in the package insert is permitted).
• Prior history of or current inflammatory joint disease other than RA (such as psoriatic arthritis, gout, reactive arthritis, Lyme disease).
• Subjects at risk for tuberculosis (TB) defined as follows: Current clinical, radiographic or laboratory evidence of active TB. Chest x-rays (posterior, anterior and lateral) obtained within the 3 months prior to obtaining written informed consent will be permitted but the images must be available and reviewed by the investigator. TB testing (IFN-gamma release assay or PPD) performed in the past month prior to Screening will be accepted; however, a copy of the report must be placed in the subject binder.
• A history of active TB.
• Subjects with a positive TB screening test indicative of latent TB including subjects currently being treated for latent tuberculosis infection (LTBI) will not be eligible for the study.
• Subjects with recent acute infection defined as:
• Any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics,
• Any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy,
• Subjects with history of chronic or recurrent bacterial infection (such as chronic pyelonephritis, osteomyelitis, and bronchiectasis etc.),
• Subjects with any history of infection of a joint prosthesis or artificial joint,
• Subjects who have a history of systemic fungal infections (such as histoplasmosis, blastomycosis, or coccidiomycosis),
• Subjects with history of recurrent herpes zoster (more than 1 episode) or disseminated (more than 1 dermatome) herpes zoster or disseminated herpes simplex, or ophthalmic zoster will be excluded,
• Symptoms of herpes zoster or herpes simplex must have resolved more than 60 days prior to screening,
• Subjects with history of primary immunodeficiency.
• Subjects with history of Human Immunodeficiency Virus (HIV) infection or who tested positive for HIV.
• Evidence of infection with hepatitis B virus (HBV), hepatitis C virus (C), human immunodeficiency virus (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening.
• Subjects who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non- metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Subjects who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.
• Current clinical findings of a history of a demyelinating disorder.
• New York Heart Association (NYHA) Class III or IV heart failure.
• Subjects who have undergone a major surgical procedure within the 60 days prior to enrollment.
• Subjects for whom 5 or more joints cannot be assessed for tenderness or swelling (i.e. due to surgery, fusion, amputation, etc.).
• Current clinical findings of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, endocrine, neurological, or cerebral disease with laboratory values as following:
• Hemoglobin level < 9.0 g/dL,
• Absolute white blood cell (WBC) count of <3.0×109/L (<3000/mm3), or absolute neutrophil count of <1.2×109/L (<1200/mm3), or absolute lymphocyte count of <0.8×109/L (<800/mm3),
• Thrombocytopenia, defined by platelet count <100×109/L (<100,000/mm3),
• Chronic kidney disease defined as Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2, based on the age-appropriate calculation,
• Proteinuria ≥3+,
• Total bilirubin (T-bili), aspartate aminotransferase (AST), alanine aminotransferase (ALT) more than 1.5 times upper limit of normal (ULN)
• Previously diagnosed hepatic cirrhosis (Child Pugh A or higher) or previously diagnosed significant liver fibrosis (> F3).
• Any form of vaccination in the last 30 days, to include but not limited to influenza, COVID, shingles, tetanus, hepatitis, pneumonia, HPV, DPT, MMR, and polio.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Rise Therapeutics LLCINDUSTRY

slinares@stjudeclinicalresearch.com305-507-2273

simon@apmedresearch.com305-400-8899

• R-2487 in Patients With Sjogren's Syndrome (SS)

  NCT06297213

  Not yet recruitingInterventionalPhase 1Updated Sep 4, 2025
• A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

  NCT00888745

  CompletedInterventionalPhase 1Updated Dec 1, 2010
• A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis

  NCT00393146

  CompletedInterventionalPhase 2Updated May 13, 2015
• Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

  NCT01055899

  CompletedInterventionalPhase 1Updated Sep 30, 2013
• A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

  NCT01026519

  CompletedInterventionalPhase 1Updated Sep 30, 2013
• A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis

  NCT04985812

  CompletedInterventionalPhase 1Updated May 23, 2025